Arcus Biosciences (RCUS) Competitors

Arcus Biosciences (NYSE:RCUS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.

Do analysts prefer RCUS or PTCT?

Arcus Biosciences currently has a consensus price target of $25.67, indicating a potential upside of 189.69%. PTC Therapeutics has a consensus price target of $63.25, indicating a potential upside of 34.00%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Arcus Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.91
PTC Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.64

Which has more volatility and risk, RCUS or PTCT?

Arcus Biosciences has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Is RCUS or PTCT more profitable?

PTC Therapeutics has a net margin of -50.32% compared to Arcus Biosciences' net margin of -102.66%. PTC Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-102.66%	-45.59%	-22.38%
PTC Therapeutics	-50.32%	N/A	-16.44%

Do insiders and institutionals have more ownership in RCUS or PTCT?

92.9% of Arcus Biosciences shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in RCUS or PTCT?

PTC Therapeutics received 377 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.57% of users gave Arcus Biosciences an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote.

Company	Underperform	Outperform
Arcus Biosciences	Outperform Votes 200 65.57%	Underperform Votes 105 34.43%
PTC Therapeutics	Outperform Votes 577 62.11%	Underperform Votes 352 37.89%

Which has stronger valuation & earnings, RCUS or PTCT?

Arcus Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Arcus Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$141M	6.65	-$307M	-$4.19	-2.11
PTC Therapeutics	$1.77B	2.11	-$626.60M	$6.51	7.25

Does the media refer more to RCUS or PTCT?

In the previous week, PTC Therapeutics had 12 more articles in the media than Arcus Biosciences. MarketBeat recorded 18 mentions for PTC Therapeutics and 6 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.50 beat PTC Therapeutics' score of 0.70 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	12 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcus Biosciences beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.